Effects of isoxuprine and nylidrin on adrenoreceptors in rat vas deferens

Peter W. Abel, A. W. Fox, K. P. Minneman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

1. The interaction of isoxuprine and nylidrin with α1- and β2-adrenoreceptors in rat vas deferens was examined using radioligand binding assays and physiological studies in vitro. 2. Isoxuprine and nylidrin have a greater affinity for binding to α1 (isoxuprine K(D) = 59 ± 15 nM; nylidrin K(D) = 41 ± 3 nM) than β2-(isoxuprine K(D) = 3,900 ± 500 nM; nylidrin K(D) = 900 ± 50 nM) adrenoreceptors in rat vas deferens. 3. Vas deferens from rats pretreated for 16-24 h with reserpine (3 mg/kg i.p.) were exposed to 10 μM phenoxybenzamine for 15 min to inactivate α-adrenoreceptors. Under these conditions high concentrations of both isoxuprine and nylidrin relaxed vas deferens contracted with 55 mM K+, however the relaxation was not blocked by the β-adrenoreceptor antagonist propranolol (10 μM). 4. Both isoxuprine and nylidrin were potent competitive antagonists of α1-adrenoreceptor mediated contraction of vas deferens. pA2 values for isoxuprine (6.9 ± .05) and nylidrin (7.1 ± .08) agreed well with K(D) values for binding to α1-adrenoreceptors in vas deferens. 5. The greater potency of isoxuprine and nylidrin in inhibiting α1-adrenoreceptors than binding to β2-adrenoreceptors or causing nonspecific relaxation suggest that α-adrenoreceptor antagonist actions of these drugs may be important in their ability to inhibit smooth muscle tone.

Original languageEnglish
Pages (from-to)213-219
Number of pages7
JournalJournal of Autonomic Pharmacology
Volume5
Issue number3
StatePublished - 1985
Externally publishedYes

Fingerprint

Nylidrin
Vas Deferens
Phenoxybenzamine
Radioligand Assay
Reserpine
Propranolol
Smooth Muscle

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Pharmacology

Cite this

Effects of isoxuprine and nylidrin on adrenoreceptors in rat vas deferens. / Abel, Peter W.; Fox, A. W.; Minneman, K. P.

In: Journal of Autonomic Pharmacology, Vol. 5, No. 3, 1985, p. 213-219.

Research output: Contribution to journalArticle

@article{e06048747ef74d829c9719ff1c804d1e,
title = "Effects of isoxuprine and nylidrin on adrenoreceptors in rat vas deferens",
abstract = "1. The interaction of isoxuprine and nylidrin with α1- and β2-adrenoreceptors in rat vas deferens was examined using radioligand binding assays and physiological studies in vitro. 2. Isoxuprine and nylidrin have a greater affinity for binding to α1 (isoxuprine K(D) = 59 ± 15 nM; nylidrin K(D) = 41 ± 3 nM) than β2-(isoxuprine K(D) = 3,900 ± 500 nM; nylidrin K(D) = 900 ± 50 nM) adrenoreceptors in rat vas deferens. 3. Vas deferens from rats pretreated for 16-24 h with reserpine (3 mg/kg i.p.) were exposed to 10 μM phenoxybenzamine for 15 min to inactivate α-adrenoreceptors. Under these conditions high concentrations of both isoxuprine and nylidrin relaxed vas deferens contracted with 55 mM K+, however the relaxation was not blocked by the β-adrenoreceptor antagonist propranolol (10 μM). 4. Both isoxuprine and nylidrin were potent competitive antagonists of α1-adrenoreceptor mediated contraction of vas deferens. pA2 values for isoxuprine (6.9 ± .05) and nylidrin (7.1 ± .08) agreed well with K(D) values for binding to α1-adrenoreceptors in vas deferens. 5. The greater potency of isoxuprine and nylidrin in inhibiting α1-adrenoreceptors than binding to β2-adrenoreceptors or causing nonspecific relaxation suggest that α-adrenoreceptor antagonist actions of these drugs may be important in their ability to inhibit smooth muscle tone.",
author = "Abel, {Peter W.} and Fox, {A. W.} and Minneman, {K. P.}",
year = "1985",
language = "English",
volume = "5",
pages = "213--219",
journal = "Autonomic and Autacoid Pharmacology",
issn = "1474-8665",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Effects of isoxuprine and nylidrin on adrenoreceptors in rat vas deferens

AU - Abel, Peter W.

AU - Fox, A. W.

AU - Minneman, K. P.

PY - 1985

Y1 - 1985

N2 - 1. The interaction of isoxuprine and nylidrin with α1- and β2-adrenoreceptors in rat vas deferens was examined using radioligand binding assays and physiological studies in vitro. 2. Isoxuprine and nylidrin have a greater affinity for binding to α1 (isoxuprine K(D) = 59 ± 15 nM; nylidrin K(D) = 41 ± 3 nM) than β2-(isoxuprine K(D) = 3,900 ± 500 nM; nylidrin K(D) = 900 ± 50 nM) adrenoreceptors in rat vas deferens. 3. Vas deferens from rats pretreated for 16-24 h with reserpine (3 mg/kg i.p.) were exposed to 10 μM phenoxybenzamine for 15 min to inactivate α-adrenoreceptors. Under these conditions high concentrations of both isoxuprine and nylidrin relaxed vas deferens contracted with 55 mM K+, however the relaxation was not blocked by the β-adrenoreceptor antagonist propranolol (10 μM). 4. Both isoxuprine and nylidrin were potent competitive antagonists of α1-adrenoreceptor mediated contraction of vas deferens. pA2 values for isoxuprine (6.9 ± .05) and nylidrin (7.1 ± .08) agreed well with K(D) values for binding to α1-adrenoreceptors in vas deferens. 5. The greater potency of isoxuprine and nylidrin in inhibiting α1-adrenoreceptors than binding to β2-adrenoreceptors or causing nonspecific relaxation suggest that α-adrenoreceptor antagonist actions of these drugs may be important in their ability to inhibit smooth muscle tone.

AB - 1. The interaction of isoxuprine and nylidrin with α1- and β2-adrenoreceptors in rat vas deferens was examined using radioligand binding assays and physiological studies in vitro. 2. Isoxuprine and nylidrin have a greater affinity for binding to α1 (isoxuprine K(D) = 59 ± 15 nM; nylidrin K(D) = 41 ± 3 nM) than β2-(isoxuprine K(D) = 3,900 ± 500 nM; nylidrin K(D) = 900 ± 50 nM) adrenoreceptors in rat vas deferens. 3. Vas deferens from rats pretreated for 16-24 h with reserpine (3 mg/kg i.p.) were exposed to 10 μM phenoxybenzamine for 15 min to inactivate α-adrenoreceptors. Under these conditions high concentrations of both isoxuprine and nylidrin relaxed vas deferens contracted with 55 mM K+, however the relaxation was not blocked by the β-adrenoreceptor antagonist propranolol (10 μM). 4. Both isoxuprine and nylidrin were potent competitive antagonists of α1-adrenoreceptor mediated contraction of vas deferens. pA2 values for isoxuprine (6.9 ± .05) and nylidrin (7.1 ± .08) agreed well with K(D) values for binding to α1-adrenoreceptors in vas deferens. 5. The greater potency of isoxuprine and nylidrin in inhibiting α1-adrenoreceptors than binding to β2-adrenoreceptors or causing nonspecific relaxation suggest that α-adrenoreceptor antagonist actions of these drugs may be important in their ability to inhibit smooth muscle tone.

UR - http://www.scopus.com/inward/record.url?scp=0022004299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022004299&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 213

EP - 219

JO - Autonomic and Autacoid Pharmacology

JF - Autonomic and Autacoid Pharmacology

SN - 1474-8665

IS - 3

ER -